Resources for Patients and their Families

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen may fight cancer by blocking the uptake of estrogen. Combining tamoxifen with chemotherapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving cisplatin and doxorubicin together with tamoxifen works in treating patients with solid tumors.

Tracking Information
First Received DateNovember 1, 1999
Last Changed DateJuly 9, 2013
Start DateMay 1994
Descriptive Information
PhasePhase 2
Study TypeInterventional
  • Adrenocortical Carcinoma
  • Brain and Central Nervous System Tumors
  • Head and Neck Cancer
  • Liver Cancer
  • Malignant Mesothelioma
  • Pheochromocytoma
  • Sarcoma
  • Drug: cisplatin
  • Drug: doxorubicin hydrochloride
  • Drug: tamoxifen citrate
  • Procedure: conventional surgery
  • Radiation: radiation therapy
Detailed Description


- Determine the feasibility and efficacy of cisplatin, doxorubicin, and tamoxifen (CAT) in patients with soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer.

- Determine the toxicity of this regimen in these patients.

OUTLINE: Patients receive cisplatin IV over 1-2 hours followed immediately by doxorubicin IV over 15-30 minutes on days 1-3 and oral tamoxifen twice daily on days 4-17. Treatment continues every 3 weeks in the absence of the total cumulative doxorubicin dose reaching at least 500 mg/m2, disease progression, or unacceptable toxicity. Patients who achieve partial remission (PR) undergo local surgery or radiotherapy, if feasible, to convert PR to complete remission.

Patients are followed every 2 months for 1 year and then every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study.

Recruitment Information
Recruitment StatusCompleted
Anticipated Enrollment30
AgesN/A - 65 Years
Accepts Healthy VolunteersNo
Eligibility Criteria


- Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability

- Patients with thyroid cancer must have failed radioactive iodine

- Measurable or evaluable disease



- 65 and under

Performance status:

- ECOG 0-2


- Granulocyte count at least 1,500/mm3

- Platelet count at least 140,000/mm3


- Bilirubin normal


- Creatinine less than 1.47 mg/dL


- Left ventricular ejection fraction at least 50% by MUGA scan

- No congestive heart failure

- No severe, uncontrolled hypertension

- No ischemia, life-threatening arrhythmia, or conduction disturbance by ECG


- No allergy to study medications

- No uncontrolled infection

- No active abuse of ethanol that would preclude treatment

- No other prior or concurrent malignancy

- Not pregnant

- Fertile patients must use effective contraception


Biologic therapy:

- Not specified


- No more than 1 prior chemotherapy regimen

- No prior anthracycline or cisplatin

- At least 3 weeks since other prior chemotherapy and recovered

Endocrine therapy:

- Not specified


- See Disease Characteristics

- No prior radiotherapy to more than 25% of bone marrow

- At least 3 weeks since other prior radiotherapy and recovered


- Not specified

Administrative Information
SponsorOttawa Regional Cancer Centre
Verification DateMay 2005
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog



What Does Cancer Remission Mean?

Diagnosing Diffuse Mesothelioma with Novel Biomarker CD47

Nicholas Hondrogen: A Prolific Art Career Abruptly Ended by Mesothelioma

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: